Gout Medication, Uloric, Proven To Have Dire Consequences
Gout is a problem that a number of Americans have to deal with. Those who live with it know that it is a constant struggle to deal with chronic pain and careful medication. Recently, new requirements have been published regarding the gout medicine, Uloric (febuxostat). A new FDA publication states that the risk for death while taking Uloric is significantly increased when compared to the risk factors of other gout medications.
What is Uloric
Gout is a chronic disease affecting around 8.3 million Americans and is characterized by swelling and pain that occurs when too much uric acid builds up in the joints. Uloric was approved in 2009 to enter the limited market of gout medication and functions by lowering the level of uric acid in the recipient’s blood. Unfortunately, while Uloric does work to reduce uric acid levels in the blood, it has also been shown to pose a risk to people taking it.
According to a report by the U.S. Food and Drug Administration (FDA), Uloric conclusively presents an increased risk of death when compared to other gout management medications such as allopurinol. In the past the gout medication has also been proven to increase the risk of gout flares with the initiation of therapy, increase the risk of cardiovascular events, hepatic toxicity, and severe skin reactions.
Potential Risks of Uloric
In a Drug Safety Announcement released on the 21st of February, the FDA is now adding a Boxed Warning, the “most prominent warning” according to the FDA. In addition to posting a new Medication Guide, the FDA has also adjusted the prescription recommendations of the medication. Under these new recommendations, Uloric is only approved for patients who have not responded adequately to allopurinol, or those who stand to suffer serious side effects from allopurinol.
While the FDA recommends disclosing any histories of heart health issues to your doctor before starting Uloric, the FDA also warns to look out for the warning signs of complications that, left untreated, can result in severe complications including death. These signs of serious complications include:
- Chest pain
- Shortness of breath
- Rapid or irregular heartbeat
- Numbness or weakness on one side of your body
- Trouble talking
- Sudden severe headache
Despite these risks, however, the FDA does not recommend stopping treatment without approval from a doctor. Failure to do so may result in more severe incidents of gout pain and inflammation.
Moving Forward After Uloric’s Black Box Update
Though these label changes will serve to increase awareness about the risks of complications and death while using Uloric, this only helps patients moving forward. If you or a loved one have suffered complications or wrongful death while taking Uloric, financial compensations may be available to you. Parker Waichman LLP knows that it’s not enough to merely correct the black box labels after the fact, they have worked to correct wrongs for many defective or poorly administered drugs including faulty vaccines. For more information about recovering compensation for heart attacks or the loss of a loved one, please read our Uloric Gout Treatment Side Effects Causes Heart Attacks and Death Lawsuit page. At Parker Waichman LLP, we are prepared to represent patients who needlessly lost their lives to complications of Uloric with a team of experienced attorneys. Contact Parker Waichman LLP today for a free consultation.
More vaccine-related cases:
New York | Brooklyn | Queens | Long Island | New Jersey | Florida
Call us at: 1-800-YOURLAWYER (800-968-7529) | Schedule your free consultation